Oncologie Revenue and Competitors
Estimated Revenue & Valuation
- Oncologie's estimated annual revenue is currently $1.3M per year.
- Oncologie's estimated revenue per employee is $100,500
- Oncologie's total funding is $96.5M.
Employee Data
- Oncologie has 13 Employees.
- Oncologie grew their employee count by -46% last year.
Oncologie's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Business Operations & Program Management | Reveal Email/Phone |
Oncologie Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Oncologie?
Oncologie, Inc., aims to advance the state of the art of precision medicine to dramatically improve the lives of people with cancer. Leveraging a deep understanding of the evolving biology of cancer, Oncologie is developing unique RNA-based biomarker panels to match patients to novel, targeted therapies that modulate the bodyￃﾢ￢ﾂﾬ￢ﾄﾢs tumor immune system and angiogenesis pathways. Oncologieￃﾢ￢ﾂﾬ￢ﾄﾢs Bavituximab is an investigational chimeric monoclonal antibody that targets the activity of phosphatidylserine and is in development for patients with gastric cancer. Oncologieￃﾢ￢ﾂﾬ￢ﾄﾢs. Navicixizumab is a bi-specific antibody targeting Delta-like ligand 4 (DLL4) in the Notch cancer stem cell pathway as well as vascular endothelial growth factor (VEGF) in development for patients with ovarian cancer and other solid tumors. Oncologie, Inc., based in Waltham, Massachusetts, and Oncologie Shanghai Co., Ltd., based in Shanghai, China, are subsidiaries of Oncologie, Ltd., and are working with global partners to acquire and further develop innovative drugs for cancer patients around the world.
keywords:N/A
$96.5M
Total Funding
13
Number of Employees
$1.3M
Revenue (est)
-46%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Oncologie News
Télésurveillance en oncologie : premières recommandations mondiales. 22/04/2022. L'ESMO a publié le 21 avril (1) ses recommandations sur le rôle des mesures...
... dat is geschreven in opdracht van de Taskforce Oncologie. 'We eindigen nu in de middenmoot, terwijl de top 3 in Europa haalbaar is',...
Bayer : nouvelle responsable du développement en oncologie ... (CercleFinance.com) - Bayer a annoncé hier la nomination, à compter du 25 avril...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.8M | 13 | -19% | $3M |
#2 | $2.1M | 13 | N/A | N/A |
#3 | $0.4M | 13 | -7% | $71.8M |
#4 | $1M | 13 | -50% | $200M |
#5 | $75M | 13 | -13% | N/A |